What guidance did OmniAb's management provide for the next earnings period?

What does OmniAb do and what are its main business segments?

What were the key takeaways from OmniAb's earnings call?

Did OmniAb beat or miss consensus estimates last quarter?

What is the market's earnings forecast for OmniAb next quarter?

What is the revenue and EPS growth rate for OmniAb year over year?

What factors drove the changes in OmniAb's revenue and profit?

What were the key takeaways from OmniAb’s earnings call?

- **Program Growth**: 399 active programs, 36 net additions YTD, with xPloration and OmniUltra driving new partnerships.
- **xPloration Momentum**: Early revenue from consumables and services, with 2026 instrument sales on the horizon.
- **OmniUltra Innovation**: Transgenic chicken platform for ultra-long CDRH3s, targeting peptide therapeutics and novel antibody formats.
- **Financial Resilience**: $59.5M cash post-private placement, with 2025 guidance for $18-22M revenue and $82-86M expenses.
- **Clinical Pipeline**: One OmnidAb-derived program entered trials, signaling new technology potential.

**【CEO Summary Section】**
- Active partners reached 104, with 399 active programs as of Q3, up 36 year-to-date. New programs added at a record pace, with Q3 additions surpassing 2024 totals.
- xPloration partner access program generated early revenue, with strong interest in its efficiency and ease of use. Consumables and service contracts are expected to drive recurring revenue.
- OmniUltra, a transgenic chicken platform producing ultra-long CDRH3s, is set to launch in December. It targets peptide therapeutics and novel antibody formats, opening new therapeutic opportunities.
- One OmnidAb-derived program entered clinical trials post-quarter end, marking a milestone for the new technology.

**【CFO Financial Commentary】**
- Q3 2025 revenue was $2.2 million, down 48% YoY due to reduced milestones and service revenue. xPloration contributed to offsetting declines.
- Operating expenses decreased to $20.4 million (from $23.9 million YoY), driven by cost reductions and headcount adjustments.
- Cash balance of $59.5 million after a $30 million private placement, with updated 2025 guidance: revenue $18-22 million, operating expenses $82-86 million.

**【Q&A Highlights】**
- **xPloration Demand**: High interest from top-tier partners, with demos aligning with 2026 capital spend planning. Instrument sales and consumables expected to boost earnings.
- **OmniUltra Launch**: Scheduled for December, targeting peptide discovery and antibody innovation. Beta testing completed, with potential for service revenue growth.
- **Milestone Delays**: Several programs pushed to 2026 due to partner priorities, though program additions remain strong.
- **Royalty Outlook**: SAL003 (anti-PCSK9) in China for 2026 launch; IMVT-1402 and acasunlimab expected to drive long-term royalty growth.

OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript

- **xPloration Breakthrough**: First system sold within weeks of launch, with high-margin consumables and subscriptions driving new revenue streams.
- **Clinical Momentum**: 32 active clinical programs, including a Phase III entry, with potential for 5-7 new trials in 2025.
- **Cost Efficiency**: $7 million annualized savings from headcount reduction, operating expenses down 16% YoY.
- **Strategic Deals**: 100 active partners and 381 programs, with 99% tied to future economics, reflecting strong deal flow and technology adoption.
- **Janssen Impact**: Trispecific antibody shows 100% response rate in myeloma, with $35 million in milestone payments tied to commercial success.


**【CEO Summary Section】**
- **Active Partners and Programs**: Ended Q2 with 100 active partners and 381 active programs, a net increase of 18 programs year-to-date. 99% of programs have potential future economics tied to OmniAb.
- **xPloration Launch Success**: Sold and installed the first xPloration system within weeks of launch, generating new revenue streams from instrument sales, consumables, and subscriptions. The system offers 10x higher throughput than competitors.
- **Clinical Pipeline Growth**: 32 active clinical programs, including 3 OmniChicken-derived antibodies in trials. A new program entered Phase III for myasthenia gravis, with potential for 5-7 new clinical entries in 2025.
- **Strategic Deal Flow**: Signed deals with Angelini Pharma, Veraxa Biotech, and others, with a focus on diversifying partner types (discovery, commercial, academic) and geographies.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025 revenue of $3.9 million, down 49% YoY due to lower milestones and service revenue (impacted by a discontinued small-molecule program). xPloration contributed to the quarter's revenue.
- **Cost Reductions**: Operating expenses decreased to $20.1 million (from $23.9 million YoY), driven by R&D and G&A savings. Headcount reduced from 114 to 87, with $7 million annualized cash savings expected.
- **Net Loss**: $15.9 million ($0.15 per share), up 16% YoY, reflecting ongoing investments in growth initiatives.
- **Cash Position**: $41.6 million as of Q2, with $2 million cash used in the quarter.
- **2025 Guidance**: Revenue $20-25 million, operating expenses $85-90 million, with xPloration expected to be additive to growth.

**【Q&A Key Highlights】**
- **xPloration Pipeline**: Over 100 active partners eligible for xPloration, with rapid adoption and interest from non-partners. Consumables and subscriptions are high-margin opportunities.
- **Technology Launches**: Planning an additional technology launch in 2025, focused on antibody discovery efficiency and novel therapeutics.
- **Janssen Trispecific Program**: $35 million milestone payments tied to first sales, with potential to shift industry standards for multiple myeloma treatment.
- **Small vs. Large Biotech Trends**: Balanced growth across large pharma, small biotech, and academic partners, with no significant impact from small biotech trial attrition.
- **OmniChicken Platform**: 3 antibodies in clinical trials, with diverse indications (oncology, inflammation, CNS), and a growing pipeline of 61 preclinical programs.


OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript

- **Partnership growth**: 95 active partners, 378 active programs, and 33 clinical-stage assets highlight expanding ecosystem.
- **Revenue resilience**: 15% YoY revenue growth to $4.2 million, offset by cost control (13% OpEx decline).
- **Exploration launch**: $500K instrument with subscription model poised to create new revenue streams.
- **Clinical momentum**: 5-7 new clinical starts expected in 2025, with SAL003 in Phase III.
- **FDA policy shift**: Streamlined toxicology requirements may accelerate antibody drug development timelines.

**【CEO Summary Section】**
- Active partners increased to 95, including new deals with Harvard's Weiss Institute, Takis Biotech, and Angelini Pharma for a Kv7.2 modulator program.
- Total active programs grew to 378, with 33 in clinical stages, including a Phase III anti-PCSK9 antibody (SAL003) with Celubris.
- Launched the Exploration Partner Access Program, allowing partners to purchase exploration instruments for $500,000 with subscription and consumables.
- 2025 expects 5-7 new clinical starts, with 39% growth in preclinical assets over two years.

**【CFO Financial Commentary】**
- Q1 2025 revenue: $4.2 million (15% YoY growth), driven by Genmab's Phase I milestone.
- Operating expenses: $23 million (13% YoY decline), with R&D down 14% and G&A down 5% due to cost control.
- Net loss: $18.2 million (-4% YoY), with cash balance of $43.6 million.
- 2025 guidance: Revenue $20-25 million, operating expenses $85-90 million (down from $90-95 million).

**【Exploration Technology Details】**
- Exploration is an AI-driven screening instrument with 1.5 million microcapillaries, enabling 10x throughput vs competitors.
- Features touchless laser sorting, no fluidics, and AI-assisted analysis for ease of use.
- Expected to generate new revenue streams via instrument sales, subscriptions, and consumables.

**【Q&A Key Takeaways】**
- Q1 program additions matched half of 2024 growth, driven by OmniAb tech adoption and workflow enhancements.
- Exploration launch feedback positive; instruments will be showcased at PEGS 2025 with potential for multi-unit sales.
- No significant tariff impact due to U.S.-built instruments and diversified supply chain.
- FDA's reduced animal testing requirements may accelerate antibody drug development, benefiting industry and partners.


OmniAb (OABI)-8 May 25-2025 Q1 Earnings call transcript

- **Partnership Expansion**: 18% YoY growth in active partners to 91, driven by new licenses with top pharma firms.
- **Pipeline Dynamism**: 12% YoY program growth to 362, with 8-10 new clinical entries forecasted for 2025.
- **Clinical Validation**: 32 active clinical programs, 5 new in 2024, supported by over 200 completed human trials.
- **Sustainability**: Double-digit growth maintained through industry cycles, 98% of programs with monetizable economics.

**【CEO Business Update】**
- **Active Partners Growth**: 18% YoY increase to 91 active partners, including new licenses with Incyte and Photinia Biosciences.
- **Active Programs Expansion**: 12% YoY growth to 362 programs, with 69 additions in Q4 offsetting 31 terminations.
- **Clinical Momentum**: 32 active clinical programs, 5 new entries in 2024 (e.g., J&J's GPRC5D and INNOLAKE's CD40 agonist), and 8-10 expected new entries in 2025.
- **Pipeline Value**: Over 98% of programs have contracted future economics, positioning for royalty revenue.

**【CFO Financial Overview】**
- **Legal Compliance**: Reviewed forward-looking statements and SEC filing references.
- **Business Model Validation**: Highlighted resilience through industry cycles, with double-digit partner and program growth despite macro challenges.
- **Clinical Trial Scale**: Over 200 human trials conducted across oncology, immunology, and other indications, reflecting partner confidence in platform efficacy.

OABI

OABI fundamentals

Earnings Call

You can ask Aime